RIO DE JANEIRO, BRAZIL - Seven months after the start of the pandemic, pharmaceutical companies - often backed by large laboratories and educational institutions - are in the process of developing an immunizing agent to neutralize Covid-19.
Currently, there are twelve vaccines in the most advanced development stage (the third phase). Two of them, developed by Moderna and Johnson & Johnson companies, have already shown preliminary results of trials in volunteers that point to 94.5 and 90 percent efficacy, respectively.
Despite the large governmental investments planned for the vaccines, the prices to be charged for the sale of these drugs have . . .